Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD: Case 2

Case Scenario 2:

January 2015

• The patient is a 72-year old female who was diagnosed with ISS stage I multiple myeloma.
• She is an insulin dependent diabetic who is experiencing peripheral neuropathy.
• Her cytogenetics were classified as standard risk, bone marrow show 50% light chain restricted plasma cells.
• M-spike IgG lambda 2.5 g/dL,
• Performance status 1.
• She received treatment with lenalidomide (25 mg daily) and low-dose dexamethasone and obtains a very good partial response.
• After a year she decided to come off of lenalidomide therapy.

      July 2016

• Six months after stopping therapy,patient had increasing fatigue and weakness.
• M-spike is now 0.8 g/dL.
• CT scan revealed several bone lesions.
• Patient was started on daratumumab, lenalidomide and dexamethasone